New Gut Cell Atlas reveals genetic origins of Crohn’s disease
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
List view / Grid view
The Gut Cell Atlas comprises 428,000 cells in the gut and sheds light on the origin of Crohn’s disease and other intestinal diseases.
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Researchers have created a tool that allows glycomics datasets to be analysed using artificial intelligence for early cancer diagnoses.
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
An NIH study used whole genome sequencing to describe three molecular subtypes of lung cancer in non-smokers, possibly improving treatments.
Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
A genetic defect in patients with inflammatory bowel disease (IBD) was found to affect how intestinal epithelial cells maintain a barrier.
Researchers have turned human stem cells into brain cells to create a new model that can predict cognitive decline rate on an individualised level.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
A new study has found mutations originating in blood progenitor cells, possibly leading to Waldenstrom macroglobulinemia (WM) therapies.